{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:34:11Z","timestamp":1793100851624,"version":"4.5.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lantern Pharma"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Limited central nervous system (CNS) bioavailability and pharmacodynamics are obstacles to effective systemic therapies for glioblastoma (GBM). One strategy to overcome these challenges is drug combinations enhancing CNS penetration and\/or tumor chemosensitivity. LP-184 (zirdafulven), a synthetic acylfulvene class alkylator, induces DNA damage and inhibits GBM cell viability in preclinical models. LP-184 is a prodrug converted to active metabolites by intracellular oxidoreductase prostaglandin reductase 1 that is overexpressed in &amp;gt;70% of GBM. DNA damage induced by LP-184 is O6-methylguanine-DNA methyltransferase (MGMT) agnostic and reversed by transcription-dependent transcription-coupled nucleotide excision repair (TC-NER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>LP-184 was evaluated in a phase Ia study (NCT05933265) in 63 adult patients with advanced malignancies, including 16 patients with recurrent GBM. All patients with GBM received prior standard-of-care therapy, and most had received one or more additional therapies before enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Treatment was overall well tolerated. Patients with GBM experienced frequent grade 1 to 2 nausea and infrequent severe thrombocytopenia and transaminitis. Clinical pharmacokinetic analysis combined with published preclinical intratumoral bioavailability data (\u223c20% penetration) predicted that LP-184 at the recommended dose for expansion (RDE) would achieve cytotoxic levels if combined with spironolactone, a brain-penetrant ERCC3 degrader and TC-NER inhibitor that sensitizes GBM cells to LP-184 3- to 6-fold. We show that three daily doses of spironolactone deplete orthotopic GBM patient-derived xenograft (PDX) ERCC3 protein by \u223c80% and increase tumor LP-184 cytotoxicity 2-fold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>LP-184 is well tolerated at the RDE, and we establish a clinically translatable plan for dosing spironolactone in combination with LP-184 for a future phase Ib\/IIa clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Treatment failure in GBM reflects inadequate drug brain exposure and DNA repair\u2013mediated resistance. LP-184 (zirdafulven), a novel acylfulvene alkylator, generates MGMT-independent DNA lesions predominantly repaired by TC-NER. In a phase Ia dose-finding trial, LP-184 was well tolerated at the RDE in participants with recurrent GBM. Plasma drug levels achieved predicted effective systemic exposures but not brain concentrations based on projected 20% brain penetrance. Pharmacokinetic modeling indicates that NER inhibition could increase tumor chemosensitivity with the addition of spironolactone. The optimal dosing regimen for spironolactone combined with LP-184 was identified in orthotopic PDX models, facilitating advancement to phase Ib\/IIa testing of LP-184 plus spironolactone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT05933265.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0518","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:49:01Z","timestamp":1791492541000},"page":"2519-2528","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-3269","authenticated-orcid":false,"given":"Karisa C.","family":"Schreck","sequence":"first","affiliation":[{"name":"1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-0276","authenticated-orcid":false,"given":"Bachchu","family":"Lal","sequence":"additional","affiliation":[{"name":"3Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6261-2364","authenticated-orcid":false,"given":"Jianli","family":"Zhou","sequence":"additional","affiliation":[{"name":"4Lantern Pharma Inc., Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-1092","authenticated-orcid":false,"given":"Hernando","family":"Lopez-Bertoni","sequence":"additional","affiliation":[{"name":"1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"3Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-3484","authenticated-orcid":false,"given":"Matthias","family":"Holdhoff","sequence":"additional","affiliation":[{"name":"2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-9775","authenticated-orcid":false,"given":"Reginald","family":"Ewesuedo","sequence":"additional","affiliation":[{"name":"4Lantern Pharma Inc., Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5319-7957","authenticated-orcid":false,"given":"Kishor","family":"Bhatia","sequence":"additional","affiliation":[{"name":"4Lantern Pharma Inc., Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5285-2807","authenticated-orcid":false,"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"4Lantern Pharma Inc., Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-5365","authenticated-orcid":false,"given":"John","family":"Laterra","sequence":"additional","affiliation":[{"name":"1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland."},{"name":"3Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,27]]},"reference":[{"key":"2026102706594392400_bib1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"Supplement_6","key":"2026102706594392400_bib2","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026102706594392400_bib3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102706594392400_bib4","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026102706594392400_bib5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2026102706594392400_bib6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"2026102706594392400_bib7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov Today"},{"key":"2026102706594392400_bib8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026102706594392400_bib9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026102706594392400_bib10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/neuonc\/noag051","article-title":"Evaluating \u201cbrain permeability\u201d: a critical issue for the development of therapeutic agents for primary and metastatic brain tumors","volume":"28","author":"Grossman","year":"2026","journal-title":"Neuro Oncol"},{"key":"2026102706594392400_bib11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/jpet.112.195768","article-title":"Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent","volume":"343","author":"Yu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2026102706594392400_bib12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12859-021-04040-8","article-title":"A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications","volume":"22","author":"Kathad","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"2026102706594392400_bib13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5582\/bst.2016.01045","article-title":"Knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis","volume":"10","author":"Xue","year":"2016","journal-title":"Biosci Trends"},{"key":"2026102706594392400_bib14","doi-asserted-by":"publisher","first-page":"717730","DOI":"10.3389\/fphar.2021.717730","article-title":"Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026102706594392400_bib15","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1078-0432.CCR-04-0442","article-title":"Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells","volume":"10","author":"Koeppel","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026102706594392400_bib16","doi-asserted-by":"publisher","first-page":"39584","DOI":"10.1074\/jbc.M400015200","article-title":"ATM-dependent CHK2 activation induced by anticancer agent, irofulven","volume":"279","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"2026102706594392400_bib17","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1535-7163.MCT-06-0427","article-title":"Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven","volume":"5","author":"Wang","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2026102706594392400_bib18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/1535-7163.MCT-22-0818","article-title":"Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies","volume":"22","author":"Restifo","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026102706594392400_bib19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2767-9764.CRC-23-0554","article-title":"LP-184, a novel acylfulvene molecule, exhibits anticancer activity against diverse solid tumors with homologous recombination deficiency","volume":"4","author":"Kulkarni","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026102706594392400_bib20","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1158\/1078-0432.CCR-23-0673","article-title":"Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma","volume":"29","author":"Lal","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026102706594392400_bib21","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1093\/nar\/gku217","article-title":"A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair","volume":"42","author":"Shahar","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026102706594392400_bib22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1535-7163.MCT-21-0613","article-title":"A preclinical study to repurpose spironolactone for enhancing chemotherapy response in bladder cancer","volume":"21","author":"Xu","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026102706594392400_bib23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"21","author":"Alekseev","year":"2014","journal-title":"Chem Biol"},{"key":"2026102706594392400_bib24","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-20-3316","article-title":"Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer","volume":"27","author":"B\u00f6rcs\u00f6k","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026102706594392400_bib25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/biom10050756","article-title":"Spironolactone and XPB: an old drug with a new molecular target","volume":"10","author":"Gabbard","year":"2020","journal-title":"Biomolecules"},{"key":"2026102706594392400_bib26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-021-00857-0","article-title":"Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications","volume":"7","author":"Lopez-Bertoni","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026102706594392400_bib27","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-026-01626-y","article-title":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","author":"Mahadevan","year":"2026  7","journal-title":"Invest New Drugs"},{"key":"2026102706594392400_bib28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","article-title":"Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma","volume":"26","author":"Vaubel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026102706594392400_bib29","doi-asserted-by":"publisher","first-page":"1033395","DOI":"10.3389\/fddsv.2022.1033395","article-title":"Artificial intelligence platform, RADR\u00ae, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors","volume":"2","author":"McDermott","year":"2022","journal-title":"Front Drug Discov"},{"key":"2026102706594392400_bib30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.18632\/oncotarget.27943","article-title":"The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations","volume":"12","author":"Kulkarni","year":"2021","journal-title":"Oncotarget"},{"key":"2026102706594392400_bib31","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","article-title":"CellMiner Cross-Database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics","volume":"49","author":"Luna","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2026102706594392400_bib32","first-page":"555","article-title":"Role of temozolomide in the treatment of cancers involving the central nervous system","volume":"32","author":"Schreck","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"2026102706594392400_bib33","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1073\/pnas.87.14.5368","article-title":"Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents","volume":"87","author":"Dolan","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102706594392400_bib34","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.bmcl.2016.02.028","article-title":"Hydroxyurea derivatives of irofulven with improved antitumor efficacy","volume":"26","author":"Staake","year":"2016","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0518\/3837744\/crc-26-0518.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2519\/3844115\/crc-26-0518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2519\/3844115\/crc-26-0518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:59:47Z","timestamp":1793098787000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2519\/789679\/Phase-Ia-Evaluation-of-LP-184-in-Recurrent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0518","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34807076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807088","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807067","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807079","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807061","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807073","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807085","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807091","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807070","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34807082","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8799848","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}